NRIX Chief Scientific Officer Hansen Gwenn Sells $36K of Stock

Hansen Gwenn, the Chief Scientific Officer at Nurix Therapeutics, Inc. (NASDAQ: NRIX), sold 1,452 shares on October 15, 2026, for a total of $36,300. The shares were sold at a price of $25.00 each, under a planned trading arrangement.

Inside Hansen's Trade

Gwenn Hansen's recent sale of 1,452 shares reflects a part of a pre-arranged plan, with the shares sold at $25.00 each. This transaction occurred while the stock is trading below its analyst price targets, which highlights a key moment for the company.

Other Institutional Activity in Nurix Therapeutics

Several other institutional investors have made moves in Nurix recently. Blackrock Inc. reduced its stake by 155,306 shares, ending with 8,770,349 shares worth about $214.2 million. In contrast, Vestal Point Capital, LP added 1,550,202 shares, bringing its total to 8,050,000 shares valued at approximately $196.6 million. Deep Track Capital, LP also increased its holdings by 1,391,458 shares, totaling 7,736,455 shares worth around $188.9 million. Rubric Capital Management LP made a significant addition as well, boosting its position by 4,753,867 shares, now holding 7,227,778 shares valued at about $176.5 million.

Nurix Therapeutics, Inc. Stock Down 0.2%

Currently, Nurix Therapeutics trades around $24.89, which is below its 50-day moving average of $25.11 and about 11.8% lower than its 52-week high of $28.23. This positioning may be a concern for investors as it indicates the stock is underperforming compared to its recent highs.

Recent Earnings

Nurix Therapeutics reported trailing twelve-month revenue of $701.9 million, with an impressive year-over-year revenue growth of 8,426.3%. The company has an EPS of $2.43 and a return on equity of 44.0%. The next earnings report is expected on January 28, 2027.

Insider Buying and Selling at Nurix Therapeutics, Inc.

In addition to Gwenn Hansen's sale, other insiders have also traded shares recently. On October 14, 2026, Director Julia P. Gregory sold 22,583 shares for about $528,528 at a price of $23.40 each. Another Director, Gregory Julia P, sold the same number of shares for a similar amount on the same day.

Analysts Set New Price Targets

On October 13, 2026, RBC Capital maintained its Outperform rating with a price target of $35.00 for Nurix. Oppenheimer also maintained an Outperform rating but adjusted its target to $32.00 from $28.00. Truist Securities kept its Buy rating with a target of $33.00, while Baird maintained an Outperform rating with a new target of $36.00, up from $33.00. Needham reiterated its Buy rating with a target of $34.00.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California. The company focuses on developing therapies for cancer and inflammatory diseases. With a market cap of about $2.67 billion, Nurix is actively working on innovative treatments in the biotechnology sector.

Bottom Line

Investors should watch for Nurix's upcoming earnings report on January 28, 2027, and further insider trading activity. With analysts holding a strong buy consensus, the company's performance will be important to monitor in the coming months.